The Effect of COVID-19 Patients' Serum Phosphate Level on Mortality in ICU

• Sponsor: Ankara City Hospital Bilkent (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT04800770
• Collaborator: (none)
• Enrollment: 160
• Location: 1
• Anticipated Duration (Months): 4.9
• Patients Per Site Per Month: 32.5

Study Details

Study Description

Brief Summary

The investigators aimed to investigate the relationship between phosphate level and mortality using the 4C Mortality Score in COVID-19 patients who were followed up in the intensive care unit.

Condition or Disease	Intervention/Treatment	Phase
Phosphate Deficiency; Covid19; Mortality	Diagnostic Test: 4C mortality score

Study Design

• Study Type: Observational [Patient Registry]
• Anticipated Enrollment: 160 participants
• Observational Model: Cohort
• Time Perspective: Cross-Sectional
• Official Title: Phosphate Levels of COVID-19 Patients and Mortality
• Actual Study Start Date: Mar 3, 2021
• Anticipated Primary Completion Date: Jun 15, 2021
• Anticipated Study Completion Date: Jul 31, 2021

Outcome Measures

Primary Outcome Measures

1. 4C mortality score [6 months]

   4C Mortality Scores of the patients will be calculated, according to age, gender, number of comorbidities, respiratory rate, SpO2, GCS, urea, and CRP parameters

2. serum phosphate levels [6 months]

   mg/dl

3. mortality [28 days]

   mortality percentage of patients in 28 days

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Participants hospitalized in the intensive care unit diagnosed with COVID-19 will incluse in the study

Exclusion Criteria:

• there is no exclusion criteria

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Ankara City Hospital	Ankara		Turkey	06800

Sponsors and Collaborators

• Ankara City Hospital Bilkent

Investigators

• Principal Investigator: betül aytaç, MD, ankara ch bilkent

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: ismail aytaç, medical doctor, Ankara City Hospital Bilkent
• ClinicalTrials.gov Identifier: NCT04800770
• Other Study ID Numbers: E1-21-1584
• First Posted: Mar 16, 2021
• Last Update Posted: Mar 16, 2021
• Last Verified: Mar 1, 2021

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by ismail aytaç, medical doctor, Ankara City Hospital Bilkent: COVID19; phosphate deficiency; 4C mortality score
• Additional relevant MeSH terms: COVID-19

Study Results

No Results Posted as of Mar 16, 2021